R008E

Peptide-Vehicle LibraryOverview
In the three years from FY 2008 to FY 2010, we promoted Okinawa Innovation Research Consignment Project"Developing cancer therapeutic drugs and test methods using peptide libraries". We designed a peptide-vehicle inwhich a cell surface recognition peptide, a cell penetrating peptide and an anticancer agent are conjugated as acandidate substance for "cell targeting therapeutic drug", and studied to construct a library. We will provide“Peptide-Vehicle Library" constructed based on the results. In recent years, problems such as QOL decrease due toside effects, patent disappearance of anticancer substances are a problem, and it is expected that drugs will bedelivered that anticancer drugs specifically to cancer cells. We hope to use it as a tool of drug discovery research.
Reference Hirata, A., Nokihara, K. Construction of peptide-vehicles, bioconjugates having modules of cancer cellsurface capture and cell-penetrating peptide with anticancer agents, Tetrahedron Lett. 2014, 55, 4091-4094.

Peptide No.

Sequence(C terminal amide)

HiPeV-001F

αTAMRA-GPKSKRKVYGRKKRRQRRR

HiPeV-002F

αTAMRA-GPKSKRKVRQIKIYFQNRRMKWKKHiPeV-003F

αTAMRA-GPKSKRKVRRRRRRRRR

HiPeV-004F

αTAMRA-GPKSKRKVRRRRNRTRRNRRRVR

HiPeV-005F

αTAMRA-GKKNQKKRYGRKKRRQRRR

HiPeV-006F

αTAMRA-GKKNQKKRRQIKIYFQNRRMKWKKHiPeV-007F

αTAMRA-GKKNQKKRRRRRRRRRR

HiPeV-008F

αTAMRA-GKKNQKKRRRRRNRTRRNRRRVR

HiPeV-009F

αTAMRA-GPKSKRKVHiPeV-010F

αTAMRA-GKKNQKKR

HiPeV-011F

αTAMRA-GYGRKKRRQRRR

HiPeV-012F

αTAMRA-GRQIKIYFQNRRMKWKKHiPeV-013F

αTAMRA-GRRRRRRRRR

HiPeV-014F

αTAMRA-GRRRRNRTRRNRRRVR

HiPeV-015F

TAMRA-G-YKQC(Acm)HKKGGKKGSG

HiPeV-016F

TAMRA-cNGRGEQcYGRKKRRQRRR

HiPeV-017F

TAMRA-cNGRGEQcRQIKIYFQNRRMKWKKHiPeV-018F

TAMRA-cNGRGEQcRRRRRRRRR

HiPeV-019F

TAMRA-cNGRGEQcRRRRNRTRRNRRRVR

HiPeV-020F

TAMRA-YGRKKRRQRRRcNGRGEQc

HiPeV-021F

TAMRA-RQIKIYFQNRRMKWKKcNGRGEQc

HiPeV-022F

TAMRA-RRRRRRRRRcNGRGEQc

HiPeV-023F

TAMRA-RRRRNRTRRNRRRVRcNGRGEQc

HiPeV-024F

FAM-GYGRKKRRQRRR

HiPeV-025F

FAM-GRQIKIYFQNRRMKWKKHiPeV-026F

FAM-GRRRRRRRRR

HiPeV-001D

C(S-EMCA-Gly-CPT)-YGRKKRRQRRR

HiPeV-002D

C(S-EMCA-Gly-Iri)-YGRKKRRQRRR

HiPeV-003D

C(S-EMCA-Gly-Eto)-YGRKKRRQRRR

HiPeV-004D

C(S-EMCA-Gly-Pac)-YGRKKRRQRRR

Peptide No.

Sequence(C terminal amide)

HiPeV-005D

Cys(S-EMCA-Gly-CPT)YGRKKRRQRRRcNGRGEQc

HiPeV-006D

Cys(S-EMCA-Gly-Iri)YGRKKRRQRRRcNGRGEQc

HiPeV-007D

Cys(S-EMCA-Gly-Eto)YGRKKRRQRRRcNGRGEQc

HiPeV-008D

Cys(S-EMCA-Gly-Pac)YGRKKRRQRRRcNGRGEQc

HiPeV-009D

Cys(S-EMCA-Gly-CPT)RQIKIYFQNRRMKWKKcNGRGEQc

HiPeV-010D

Cys(S-EMCA-Gly-Iri)RQIKIYFQNRRMKWKKcNGRGEQc

HiPeV-011D

Cys(S-EMCA-Gly-Eto)RQIKIYFQNRRMKWKKcNGRGEQc

HiPeV-012D

Cys(S-EMCA-Gly-Pac)RQIKIYFQNRRMKWKKcNGRGEQc

HiPeV-013D

Cys(S-EMCA-Gly-CPT)RRRRRRRRRcNGRGEQc

HiPeV-014D

Cys(S-EMCA-Gly-Iri)-RRRRRRRRR
cNGRGEQc

HiPeV-015D

Cys(S-EMCA-Gly-Eto)RRRRRRRRRcNGRGEQc

HiPeV-016D

Cys(S-EMCA-Gly-Pac)RRRRRRRRRcNGRGEQc

HiPeV-017D

Cys(S-EMCA-Gly-CPT)RRRRNRTRRNRRRVRcNGRGEQc

HiPeV-018D

Cys(S-EMCA-Gly-Iri)RRRRNRTRRNRRRVRcNGRGEQc

HiPeV-019D

Cys(S-EMCA-Gly-Eto)RRRRNRTRRNRRRVRcNGRGEQc

HiPeV-020D

Cys(S-EMCA-Gly-Pac)RRRRNRTRRNRRRVRcNGRGEQc

HiPep Laboratories Nakatsukasa-cho 486-46, Kamigyo-ku, Kyoto, 602-8158, JAPANTEL: 075-813-2101, FAX: 075-801-0280, E-mail: info@hipep.jp, URL: http://www.hipep.jp/